1. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma 
James E. Fish, MDa, Jill P. Karpel, MDb, Timothy J. Craig, DOc, George W. Bensch, MDd, Michael Noonan, MDe, D.Robert Webb, MDf, Bernard Silverman, MDg, Eric J. Schenkel, MDh, Anthony R. Rooklin, MDi, Joe W. Ramsdell, MDj, Robert Nathan, MDk, Jeffrey G. Leflein, MDl, Jay Grossman, MDm, David F. Graft, MDn, Richard G. Gower, MDo, Stuart M. Garay, MDp, Evangelo Frigas, MDq, Arthur C. DeGraff, MDr, Edwin A. Bronsky, MDs, David I. Bernstein, MDt, William Berger, MDu, Lucy Shneyer, MSv, Keith B. Nolop, MDv, Judy E. Harrison, MDv 
Journal of Allergy and Clinical Immunology 
Volume 106, Issue 5, Pages (November 2000)
DOI: /mai
Copyright © 2000 Mosby, Inc. Terms and Conditions

2. Fig. 1
Kaplan-Meier estimates of time to asthma worsening (treatment failure). Both MF dry powder inhaler treatment groups had a greater probability of remaining in the study compared with the placebo group (P < .01). BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

3. Fig. 2
Effects of MF dry powder inhaler on prednisone use. The means of the individual percentage changes are shown over 12 weeks and at endpoint. Asterisks indicate values that are significantly different from those of the placebo group (P < .05). BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

4. Fig. 3
The distribution of prednisone dose reduction from baseline to endpoint. BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions

5. Fig. 4
Effects of MF dry powder inhaler on mean change in FEV1 from baseline are shown over 12 weeks and at endpoint. Asterisks indicate values that are significantly different from those of the placebo group (P < .05). Number signs indicate values at endpoint that are significantly different from those at baseline (P < .05). BID, Twice daily.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2000 Mosby, Inc. Terms and Conditions